BioNTech SE - ADR vs AT&T Inc. — how do they compare? BioNTech SE - ADR trades at $90.53 (market cap $23.31B), while AT&T Inc. trades at $24.49 (market cap $164.80B). The key difference: AT&T Inc. is far larger — about 7.1× BioNTech SE - ADR's market cap, and AT&T Inc. pays a 4.62% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | T | |
|---|---|---|
Market Cap | $23.31B | $164.80B |
Sector | Health | Media |
52-Week High | $119.34 | $29.62 |
52-Week Low | $83.89 | $20.49 |
Enterprise Value | $6.60B | $310.12B |
Dividend Yield | — | 4.62% |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.67, up 2.72% today, with a bullish technical signal and strong analyst support. The stock faces fundamental challenges, including declining COVID-19 vaccine revenue and negative profitability, but holds a robust cash position of $16.78 billion. Recent news highlights leadership changes and pipeline advancements in oncology, with a consensus price target of $121.00 implying significant upside potential.
Outlook: Long-term growth hinges on oncology pipeline success, but near-term risks from vaccine demand volatility and net losses persist. Investment opportunity lies in discounted valuation relative to cash and pipeline assets, though execution risks and competitive pressures require careful monitoring.
AT&T (T) trades at $23.80, up 0.38% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.69. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.65 exceeding the $0.59 estimate. Revenue grew to $125.65 billion in 2025, and net income surged to $21.95 billion, reflecting a robust profit margin of 17.47%. Recent news highlights fiber expansion and 5G network investments.
The outlook is positive, supported by improving cash flow, strategic investments, and a 4.8% dividend yield. However, risks include competitive pressure from new entrants like SpaceX's Starlink and high debt levels. Analyst sentiment is mixed but leans bullish, with 41% buy ratings. The stock presents a value opportunity with a low P/E of 7.85, but investors should monitor execution on growth initiatives.
Trailing returns across standard periods
Latest headlines on both assets
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →